ClinicalTrials.gg
Not yet recruitingNCT07078305Updated Jul 22, 2025

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

A Phase 2 interventional study of Regorafenib and tislelizumab and Regorafenib in Hepatocellular Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.

Planned enrollment
4th of 22
134 · median 33
Started
2025
the only one that year
Phase 2
16 of 22
6 open now
Registered
19th of 22
by date

Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 16 in phase 2, and was the 19th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing regorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy. Based on the above research background, we believe that the combination of PD-1 inhibitors and multi-target inhibitors is a promising treatment option for second-line liver cancer. Our study aims to explore the efficacy and safety of trastuzumab monoclonal antibody combined with regorafenib compared to regorafenib monotherapy for second-line treatment of advanced hepatocellular carcinoma after previous target immunotherapy progression.

Read the detailed description

According to GLOBOCAN2020 statistics, in 2020, there were 906000 new cases and 830000 deaths of liver cancer worldwide, making it the seventh most common cancer and the fifth leading cause of cancer death. East Asia, especially China, Japan, and South Korea, is a high-risk area for liver cancer, with China accounting for approximately 50% of the world's new liver cancer cases each year. Epidemiological data show that hepatitis B virus (HBV) infection is the main reason for the high incidence of liver cancer in China. Liver cancer in our country is discovered late and staged late. Most patients have lost the opportunity for surgical resection when they seek medical attention, and the overall prognosis is poor. The 5-year survival rate is about 12.5%.

In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of HCC and has gradually become the cornerstone of advanced liver cancer treatment. The global multicenter Phase III IMbrave150 clinical study compared the combination of atezolizumab and bevacizumab ("T+A" regimen) with sorafenib. The results showed that the overall survival was 19.2 months compared to 13.4 months (HR 0.66, p\<0.001), and the progression free survival was 6.9 months compared to 4.3 months (HR 0.65, p\<0.001). Compared with sorafenib, the "T+A" regimen significantly improved the overall survival and progression free survival of unresectable HCC patients. In the 194 Chinese patient population, the median OS was 24.0 months compared to 11.4 months (HR 0.53), which is consistent with global benefits. Another randomized, open label, phase II-III ORIENT-32 study showed that the combination of Sintilimab and bevacizumab biosimilar ("Shuangda" regimen) significantly improved patient efficacy compared to sorafenib, significantly reduced the risk of death and progression, improved ORR and quality of life, and subgroup analysis showed similar benefits. The median overall survival of the two groups was 10.4 months (HR=0.569, p\<0.001), progression free survival was 4.6 months compared to 2.8 months (HR=0.565, p\<0.001), ORR was 21% compared to 4%, and DCR were 72% and 64%, respectively. The combination of Shuangda and each individual drug and potential disease has known safety and good tolerability. Currently, the combination therapy of immune checkpoint inhibitors (anti-PD-1/L1) and anti angiogenic drugs has become the standard treatment for unresectable advanced HCC. Although targeted therapy and immunotherapy have made breakthroughs in the field of liver cancer and continuously extended patient survival, first-line treatment inevitably leads to drug resistance. About 30% of patients cannot achieve objective relief due to primary drug resistance, and the median progression free survival of other patients with first-line treatment is about 4-7 months, followed by secondary drug resistance.

In the second-line treatment of advanced liver cancer, multiple immune monotherapy and anti angiogenic drug monotherapy are recommended by guidelines. The KEYNOTE-394 study enrolled second-line hepatocellular carcinoma (HCC) patients who experienced progression after treatment with sorafenib or oxaliplatin, or were intolerant to sorafenib or oxaliplatin treatment, and randomly assigned them to pembrolizumab+BSC (best supportive treatment) or placebo+BSC. The study results showed that compared with the control group, the pembrolizumab group significantly prolonged the median OS of patients (14.6 months compared to 13.0 months), HR=0.79,P=0.0180), The 2-year OS rate of the pembrolizumab group was 34.3%, higher than the control group's 24.9%, and the long-term survival benefit was more significant. The median PFS was 2.6 months compared to 2.3 months (HR=0.74, P=0.0032, 2-year PFS rates were 11% and 0%, respectively), and the ORR was 12.7% compared to 1.3%. A global multicenter, randomized, double-blind, placebo-controlled phase III clinical trial of regorafenib in liver cancer patients who had previously received sorafenib treatment showed that after sorafenib treatment, regorafenib significantly reduced the risk of death and disease progression compared to the placebo control group, with a median OS of 10.6 months compared to 7.8 months (HR=0.63, P\<0.0001) and a median PFS of 3.1 months compared to 1.5 months (HR=0.46, P\<0.0001). However, the above clinical studies included participants who had previously received immunotherapy. In the current situation where target immunotherapy is the mainstream first-line treatment, the recommended plan for second-line treatment is still uncertain. A multicenter real-world study in the Asia Pacific region exploring the progression of first-line treatment with the A+T regimen followed by the selection of second-line system regimens. The median PFS of sorafenib, lenvatinib, and regorafenib were 2.3 months (95% CI 2.0-2.6), 4.0 months (95% CI 3.5-4.9), and 3.6 months (95% CI 2.7-5.4), respectively. The median OS of regorafenib was 6.3 months (95% CI 5.3-7.8), 8.0 months (95% CI 7.0-10.9), and 9.7 months (95% CI 5.2-NR), respectively. The median OS of regorafenib was higher than the other two TKIs. It is worth noting that choosing TKI combined with immune checkpoint inhibitors (IO) as the second-line treatment regimen resulted in higher median PFS and OS than TKI monotherapy, at 5.4 months (95% CI 3.0-8.8) and 12.6 months (95% CI 9.8-NR), respectively.

Although monotherapy immunotherapy or anti angiogenic therapy brings certain benefits to second-line HCC patients, the efficacy is far from meeting clinical needs. Based on the synergistic effect of immunotherapy and anti angiogenic therapy, the combination therapy of the two is also constantly being explored. The JVDJ study showed that the combination of Remdesizumab and Duvalimumab in the treatment of HCC with previous treatment failure had an ORR of 11%, DCR of 61%, median PFS of 4.4 months, and median OS of 10.7 months. The efficacy was better in patients with high PD-L1 expression. A retrospective multicenter study showed that the combination of xindilimab and regorafenib for second-line treatment of advanced liver cancer after first-line sorafenib or lenvatinib treatment resulted in an ORR of 24.1%, DCR of 74.1%, median PFS of 5.6 months, and median OS of 13.4 months.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinoma
  • Regorafenib
  • Tislelizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign a written form;
  • Age ≥ 18 years old, both male and female are eligible;
  • Hepatocellular carcinoma (HCC) diagnosed by organization/pathology or imaging that meets the AASLD diagnostic criteria;
  • HCC that has received targeted immunotherapy in the past (regardless of whether local treatment is received or not, excluding therapy), including atezolizumab+bevacizumab, sintilizumab+bevacizumab analogs, carizolizumab+apatinib, and other /L1 drugs+TKI, and whose disease progression has been confirmed by imaging;
  • score ≤ 7;
  • According to 1.1 criteria, there must be at least one ;
  • PS score 0-1;
  • Expected survival period greater than 12 weeks;
  • The function of important organs meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days):

    1. Blood routine:

      Neutrophils ≥ 1.5 × 109/L count ≥ 80 × 109/L ≥ 90g/L;

    2. Liver and kidney function:

Serum creatinine (SCr) ≤ 1.5 times the (ULN) or rate ≥ 50 ml/min (Cockcroft Gault formula); Total (TBIL) ≤ 3 times the upper limit of normal (ULN); or ALT levels ≤ 5 times the upper limit of normal (ULN); Urinary protein\<2+; If urine protein is ≥ 2+, the 24-hour urine protein quantification must show protein ≤ 1g;

  • Normal coagulation function, no active bleeding or thrombotic diseases

    1. International Standardization Ratio ≤ 1.5 × ULN;
    2. Partial thromboplastin time APTT ≤ 1.5 × ULN;
    3. Prothrombin time PT ≤ 1.5 × ULN;
  • Non surgical sterilization or female patients of childbearing age are required to use a medically approved measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo non-surgical sterilization must have a negative serum or urine HCG test within 7 days prior to enrollment in the study; And it must be during non lactation period; Non surgical sterilization or male patients of childbearing age need to agree to use a medically approved contraceptive measure with their spouse during the study treatment period and within 3 months after the end of the study treatment period.

Exclusion criteria

Exclusion Criteria:

  • The subject has previous or concurrent malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);
  • It is known that the subject has a history of allergies to large molecule protein preparations, or is known to be allergic to the drug or drug components;
  • Within the past 6 months, there have been incidents of esophageal or gastric variceal bleeding caused by portal hypertension; Within 3 months prior to the first administration, severe (G3) varicose veins were identified through endoscopic examination; Evidence of portal hypertension (including imaging findings of splenomegaly), assessed by researchers as high-risk for bleeding
  • Any life-threatening bleeding events that have occurred within the past 3 months, including the need for blood transfusion therapy, surgery or local treatment, and continuous medication therapy
  • Subjects with any active disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, those who have undergone thyroid surgery in the past cannot be included; subjects with vitiligo or complete remission of childhood asthma without any intervention in adulthood can be included; subjects with asthma requiring bronchodilators for medical intervention cannot be included);
  • The subject is currently using , systemic, or absorbable local hormone therapy to achieve immunosuppression (dose>10mg/day prednisone or other therapeutic hormones), and has continued to use it within 2 weeks before enrollment;
  • Ascites or pleural effusion with clinical symptoms that require therapeutic puncture or regular drainage (≥ 1 time/month);
  • Patients with uncontrolled clinical symptoms or diseases of the heart, such as: (1) grade 2 or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, and (4) supraventricular or ventricular arrhythmias requiring treatment or intervention;
  • The subject has an active infection or an unexplained fever greater than 38.5 degrees Celsius during the screening period or before the first administration (according to the researcher's judgment, the subject can be included if the fever is caused by the tumor);
  • Patients with objective evidence of past and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of lung function, etc;
  • Subjects with congenital or acquired immune dysfunction, such as infected individuals;
  • Within less than 4 weeks before the study medication, or possibly during the study period, receiving a ;
  • The subject is known to have a history of substance abuse, alcoholism, or drug use;
  • Have received Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications within 2 weeks before the first administration.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug: Regorafenib and tislelizumab

  • Active comparator
    Control group

    Drug: Regorafenib

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    Progression free survival

    Time frame: 1 year

Secondary outcomes

  1. ORR

    Objective response rate

    Time frame: 6 months

  2. DCR

    Disease Control Rate

    Time frame: 6 months

  3. OS

    Overall survival

    Time frame: 1 year

  4. AE

    Adverse events

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2026, 12 months later.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 12 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2025
First posted
Jul 22, 2025
StartEst.
Aug 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2027
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07078305
Responsible party
Sponsor
First posted
Jul 22, 2025
Start date
Aug 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Regorafenib · Tislelizumab

Start the discussion